Adaptimmune Therapeutics PLC - ADAPY

Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
Website: No information yet · Social: No information yet

Company profile

Powered by TradingView

Quarter snapshot

Latest / Compare
Q4 2025 · Q3 2025
Value (USD)
Total reported value ($000)
$77K
QoQ value delta ($000)
-$5.404M (-98.6%)
Implied price effect (QoQ)
-64.17%
Shares
Total shares
1,660,904
QoQ shares delta
-40,704,342 (-96.08%)
Total shares held by funds (by quarter)
Shares (left)

Fund holders include prior positions carried forward until a new 13F confirms a change. Reported holders have reported a position in this security for that quarter; this is not the total number of 13F filers.

Market chart (ADAPY)

Powered by TradingView
Interactive chart by TradingView.

Top holders (Q4 2025)

Top 25 only Full list
Early Q1 2026 data: only 1 institutional holders reported so far. More will appear as funds file with the SEC.
Manager Value ($000) Shares % of 13F
JOSH ARNOLD INVESTMENT CONSULTANT, LLC 37 20,000 0.03%
Empirical Finance, LLC 20 800,000 0.0%
Rathbones Group PLC 11 432,818 0.0%
XTX Topco Ltd 9 353,836 0.0%
BARCLAYS PLC 0 2,532 0.0%
ACADIAN ASSET MANAGEMENT LLC 0 17,167 0.0%
RHUMBLINE ADVISERS 0 3,661 0.0%
SIMPLEX TRADING, LLC 0 18,610 0.0%
X-Square Capital, LLC 0 11,359 0.0%
TD Waterhouse Canada Inc. 0 14 0.0%
Raiffeisen Bank International AG 0 907 0.0%